Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 25Carcinoma, Non-Small-Cell Lung 14Squamous Cell Carcinoma of Head and Neck 11Melanoma 10Breast Neoplasms 10Urinary Bladder Neoplasms 9Colorectal Neoplasms 9Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Adenocarcinoma Of Esophagus 6Ovarian Neoplasms 5Liver Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Mesothelioma, Malignant 4Head and Neck Neoplasms 4Neoplasm Metastasis 3Mesothelioma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Vaginal Neoplasms 2

Interventions

Liver Transplantation 4Gemcitabine 4Cisplatin 4Capecitabine 4Radiosurgery 3toripalimab 2Specimen Handling 2Self Expandable Metallic Stents 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1Saline Solution 1Radiofrequency Ablation 1Photosensitizing Agents 1Photochemotherapy 1Pancreatic Hormones 1Optical Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Klatskin Tumor × tremelimumab × Clear all
NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡